Related topics: Regulatory & Safety
Titan Pharmaceuticals is to lay-off 40 per cent of its workforce at it attempts to lower operating expenses and preserve capital.
In doing so Titan will make cut backs to clinical and manufacturing development activities, operating them at a minimal level. This will allow Titan to focus on realising “the potential value of its assets, particularly the Probuphine program”.
Further staff reductions are anticipated in the coming weeks.
Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions